Please ensure Javascript is enabled for purposes of website accessibility

Why Endo International and BioSpecifics Technologies Stocks Soared Today

By Keith Speights – Oct 19, 2020 at 4:25PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

Investors are fired up about Endo's planned acquisition of BioSpecifics.

What happened

Shares of Endo International (ENDP -0.83%) and BioSpecifics Technologies (BSTC) were soaring 13.9% and 45.1%, respectively, as of 3:31 p.m. EDT on Monday. The big gains came after Endo announced plans to acquire BioSpecifics Technologies for $540 million net of cash acquired in the deal.

So what

It makes perfect sense why BioSpecifics Technologies share price took off. Endo's offer of $88.50 per share represented a 45% premium over the closing price of the small biotech stock on Friday. 

Fingers holding two jigsaw puzzle pieces close to each other and ready to lock into place.

Image source: Getty Images.

Why did Endo's share price jump? Investors appeared to really like the company's move to acquire BioSpecifics.

The match between the two companies seems to be a good one. Endo and BioSpecifics have been partners since 2004. BioSpecifics originally developed collagen-based therapy Xiaflex, which was licensed and marketed by Endo. Another product included in the collaboration agreement between the two drugmakers, injectable cellulite treatment Qwo, has already won approval from the U.S. Food and Drug Administration (FDA) and is on track to be launched commercially in the first half of next year.

Endo CEO Blaise Coleman stated that the acquisition of BioSpecifics is part of the company's strategy to invest in "the significant long-term growth potential" of Xiaflex and Qwo. Coleman added that the deal will immediately boost Endo's adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) and "create significant value for shareholders of both organizations."

Now what

Endo's planned acquisition of BioSpecifics has already been unanimously approved by the boards of directors of both companies. A major shareholder of BioSpecifics, the Edwin H. Wegman Marital Trust, has also already committed to tendering its shares in support of the deal. The two companies expect the transaction to close later this year. 

Keith Speights has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.